-
Artemisinin-a gift from traditional Chinese medicine for thousands of years
Time of Update: 2022-01-10
"The successful research and development of artemisinin-based antimalarial drugs is both the pride of China's medical and academic circles, and it is also our country's regret!" Artemisinin-based drugs are gifts from traditional Chinese medicine.
-
Junshi Biologics subcutaneous injection preparation JS001sc injection clinical application is accepted
Time of Update: 2022-01-10
Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
3 mg/kg, JS001sc administered by subcutaneous injection and Terry administered by intravenous injection The anti-tumor effect of prilimumab was equivalent, and no significant difference was seen .
-
Discussion: Development of dissolution methods for oral solid preparations
Time of Update: 2022-01-10
In the early stage of formulation development, when the dissolution test of tablets or capsules has not reached the standard, it may indicate the need to adjust the prescription and process, or the dissolution method .
-
Ruige Pharmaceutical's new generation of CDK2/4/6 small molecule inhibitors received clinical approval in the U.S.
Time of Update: 2022-01-09
The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer .
-
The latecomers are on top: the growth path of atorvastatin
Time of Update: 2022-01-09
After being artificially synthesized for the first time, atorvastatin has undergone a series of developments, including the improvement of the synthesis process, the active exploration of indications, the improvement of side effects, the expansion of the market, the birth of generic drugs, and so on .
-
Guangzhou Pharmaceutical Group builds Macau's first GMP standard Chinese patent medicine factory
Time of Update: 2022-01-09
At the beginning of 2020, with the goal of promoting cooperation between Guangdong and Macao, assisting the moderately diversified economic development of Macao, and accelerating the internationalization of Chinese medicine, Guangzhou Pharmaceutical Group established an international headquarters in Macao, and quickly began to prepare a GMP-compliant Chinese patent medicine production base in Macao to help promote The production of Chinese patent medicines in Macau is standardized and standardized .
-
Tianjing Bio-B7-H3 monoclonal antibody was approved for Phase 2 clinical trials in China
Time of Update: 2022-01-09
Tianjing Bio (NASDAQ: IMAB) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has formally approved ebrotuzumab (also known as TJ271) and pembrolizumab (Keytruda) Phase 2 clinical trial of combined treatment of solid tumors (including non-small cell lung cancer, urothelial cancer and other tumor types) .
-
List of domestic drug R&D failure cases in 2021
Time of Update: 2022-01-09
(1) On February 8, Biotech announced that its ADC drug BAT8001 (recombinant humanized anti-HER2 monoclonal antibody-maytansine conjugate for injection) phase III clinical efficacy indicators did not reach the preset level compared with the control group It was decided to terminate the clinical trial of the project, and the total R&D investment of the project was 226 million yuan .
-
Blood test breakthrough may promote Alzheimer's disease and Parkinson's disease diagnosis
Time of Update: 2022-01-09
Quanterix, another test and research company, said that compared with amyloid beta, measuring certain types of tau in blood samples may better explain the progress of the disease.
-
Patient recruitment: clinical trial of patients with systemic myasthenia gravis
Time of Update: 2022-01-08
Drug Information: Bartolizumab (HBM9161) Bartolizumab (HBM9161) is a fully human monoclonal antibody (mAb) that can block the binding of FcRn-IgG to each other and accelerate the elimination of IgG in the body, thereby achieving effective The effect of treating pathogenic IgG-mediated autoimmune diseases .
-
First-in-class drug design series: A review of the development of Pfizer’s oral anti-coronavirus drug Paxlovid
Time of Update: 2022-01-08
The oral absorption of cyano group-introduced compound 2 was significantly improved in rats and maintained good metabolic stability, but the inhibitory effect on the main protease in vitro and the anti-SARS-CoV-2 virus activity were reduced .
-
Severe protection rate of 96%, Cansino adenovirus vector new crown vaccine phase III clinical results announced
Time of Update: 2022-01-08
This international multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluated the effectiveness, safety, and immunogenicity of a single dose of Kevisa in adults 18 years and older .
5% effectiveness in preventing symptomatic COVID-19 disease 28 days after vaccination and 91.
-
Top 10 most promising drug trial data
Time of Update: 2022-01-08
This year, all three vaccines have achieved positive results in the main mid-term trials of stimulating RSV neutralizing antibodies, and they are all in phase 3 studies, and data is expected to be released in 2022 .
-
Hengrui Medicine's 2 innovative drugs were approved for listing, reaching 10 innovative drugs
Time of Update: 2022-01-07
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients .
-
The heart-pounding clofenac-bringing you closer to the rare disease "heart amyloidosis"
Time of Update: 2022-01-07
As the first-in-class molecule in TTR stabilizers, clofenac is the only drug approved by the FDA for the treatment of ATTR-CM.
Phase II clinical studies have confirmed that during the treatment with clofenac, genetic TTR and The TTR stability of patients with wild-type TTR cardiac amyloidosis has been improved.
-
Nanjing Chia Tai Tianqing is showing off!
Time of Update: 2022-01-07
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan .
-
Aside from the cloud, what are the key points of non-clinical research on genetically modified cell therapy products?
Time of Update: 2022-01-07
The Drug Evaluation Center has conducted industry research, document collection and Expert consultation seminars and other work, based on the existing "Technical Guidelines for Research and Evaluation of Cell Therapy Products" (for trial implementation), and based on the current scientific understanding of genetically modified cell therapy products, A brief introduction to the relevant laws and regulations and policy framework of the "Guiding Principles of Clinical Research Technology (Trial)" .
-
Significant progress has been made in the research of Chinese scientists in response to Omi Keron
Time of Update: 2022-01-07
Researchers from Jimin Credential found that the binding ability of JMB2002 with the spike protein of Omi Keron mutant strain was 4 times higher than that of the wild-type strain (Figure 2A) The joint team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Jimin Credential successfully The structure of the spike protein of Omi Keron variant strain and the specific therapeutic antibody JMB2002 was analyzed (Figure 2C).
-
Yuandong and Aosaikang grab the first imitation sword for children's medicine and target 5 billion large varieties
Time of Update: 2022-01-02
Figure 1: The situation of companies that recently reported the production of esomeprazole magnesium enteric-coated dry suspension Source: CDE official website Figure 2: Sales Trend of Esomeprazole (Unit: Ten Thousand Yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern Esomeprazole is a single S isomer of omeprazole, and it is also the first drug with only one optical isomer among proton pump inhibitors.
-
All in one article: Five types of biotech drugs commonly used in registration applications
Time of Update: 2022-01-01
Products; and here specifically refers to therapeutic drugs produced by recombinant DNA technology or other innovative biotechnology, such as cytokines, plasminogen activators, recombinant plasma factors, growth factors, fusion proteins, receptors, vaccines and monoclonal antibodies, stem cells treatment technology .
